We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · August 02, 2021

Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp

The British Journal of Dermatology


Additional Info

The British Journal of Dermatology
Efficacy and Safety of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis of the Scalp: Results up to 32 Weeks From a Randomized, Phase III Study
Br J Dermatol 2021 Mar 24;[EPub Ahead of Print], AS Van Voorhees, L Stein Gold, M Lebwohl, B Strober, H Sofen, K Papp, J Bagel, Z Zhang, M Paris, Y Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading